Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Ronald van Vollenhoven(Amsterdam University Medical Centers), Matthias Schneider(Justus-Liebig-Universität Gießen), Carlos Vasconcelos(Hospital de Santo António), Ann E. Clarke(University of Calgary), Dimitrios Boumpas(University of Crete), W. Graninger(Medical University of Graz), Anisur Rahman(University College London), Adrian Levitsky(Karolinska Institutet), Alexandre E. Voskuyl(Amsterdam Neuroscience), Anna Jędryka-Góral(National Institute of Geriatrics, Rheumatology and Rehabilitation), Frédéric Houssiau(Cliniques Universitaires Saint-Luc), Elena Zakharova(Ministry of Health of the Russian Federation), George Βertsias(University Hospital of Heraklion), Eric F. Morand(Novartis (Switzerland)), Ricard Cervera(Hospital Clínic de Barcelona), Anne Voss(Odense University Hospital), Caroline Gordon(University of Birmingham), Ian N Bruce(University of Manchester), Xavier Mariette(Inserm), N. Costedoat‐Chalumeau(Délégation Paris 5), Hendrika Bootsma(University Medical Center Groningen), David Isenberg(Regenerative Medicine Institute), Jozef Rovenský(National Institute of Rheumatic Diseases), David Jayne(University of Cambridge), Roger A. Levy(Universidade do Estado do Rio de Janeiro), Kirsten Lerstrøm, Murat İnanç(Istanbul University), Søren Jacobsen(University of Copenhagen), Thomas Dörner(German Rheumatism Research Centre), Martin Aringer(University Hospital Carl Gustav Carus), Annegret Kuhn(University of Passau), Ronald H. W. M. Derksen(University Medical Center Utrecht), László Czirják(University of Pecs), Sandra Navarra(University of Santo Tomas Hospital), Josef S Smolen(Leiden University Medical Center), Asad Zoma(NHS Lanarkshire), Irmgard Neumann(Wilhelminen Hospital), Marta Mosca(University of Pisa)
Cited by 726
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
|Annals of the Rheumatic Diseases|2019|1.5k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k